Surgical Resection and Pazopanib Treatment for Recurrent Cardiac Angiosarcoma.
angiogenesis
cardiac angiosarcoma
pazopanib
Journal
Clinical pathology (Thousand Oaks, Ventura County, Calif.)
ISSN: 2632-010X
Titre abrégé: Clin Pathol
Pays: United States
ID NLM: 101741182
Informations de publication
Date de publication:
Historique:
received:
03
01
2019
accepted:
09
01
2019
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
19
6
2019
Statut:
epublish
Résumé
Cardiac sarcoma treatment is challenging for surgeons because of frequent tumor recurrence and poor prognosis. In addition, optimal management of recurrences is not well established. The multi-targeted tyrosine kinase inhibitor, pazopanib, was recently approved for soft-tissue sarcoma. Herein, we present a case involving recurrent cardiac angiosarcoma where the patient survived for 2 years with complete remission of disease after repeated surgical resection and treatment with oral pazopanib. Based on our experience, aggressive surgical resection combined with pazopanib may be a valid treatment for recurrent cardiac angiosarcoma to improve patient survival.
Identifiants
pubmed: 31211293
doi: 10.1177/2632010X19831261
pii: 10.1177_2632010X19831261
pmc: PMC6546942
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2632010X19831261Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Cancer J. 2005 May-Jun;11(3):241-7
pubmed: 16053668
Cancer. 2008 Jun;112(11):2440-6
pubmed: 18428209
Ann Surg Oncol. 2012 Aug;19(8):2707-15
pubmed: 22476752
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Eur J Cancer. 2014 Jan;50(1):128-36
pubmed: 24135684
Ann Thorac Surg. 2014 Apr;97(4):1379-85
pubmed: 24565404
J Natl Compr Canc Netw. 2016 May;14(5):499-502
pubmed: 27160228
Case Rep Oncol. 2016 Jun 27;9(2):363-7
pubmed: 27462238